Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Genmab ( (GMAB) ).
Genmab A/S has completed a previously announced share buy-back program initiated on February 17, 2026, to meet obligations under its Restricted Stock Unit program. The company finished the program ahead of the March 31, 2026 deadline, repurchasing the full 342,130 shares for a total consideration of about 615.1 million DKK.
From March 9 to March 13, 2026, Genmab acquired 93,130 shares, bringing its treasury stock to 2,859,663 shares, or roughly 4.45% of its share capital and voting rights. The buy-back, conducted under EU market abuse and safe-harbour regulations, modestly consolidates existing shareholders’ ownership and underlines Genmab’s continued use of equity-based compensation within its capital management strategy.
The most recent analyst rating on (GMAB) stock is a Hold with a $28.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
Spark’s Take on GMAB Stock
According to Spark, TipRanks’ AI Analyst, GMAB is a Neutral.
The score is supported by strong financial performance (rapid growth, high margins, solid cash generation) and a constructive earnings outlook with meaningful pipeline catalysts, but is held back by the sharp 2025 leverage increase and weaker earnings quality signals, plus bearish near-term technical momentum despite oversold readings.
To see Spark’s full report on GMAB stock, click here.
More about Genmab
Genmab A/S is an international biotechnology company focused on developing innovative antibody-based medicines for cancer and other serious diseases. Founded in 1999 and headquartered in Copenhagen, it has built a broad portfolio of bispecific antibodies, antibody–drug conjugates and other next-generation modalities, powering eight approved antibody therapies and a sizable late-stage clinical pipeline across global markets.
Average Trading Volume: 1,743,038
Technical Sentiment Signal: Sell
Current Market Cap: $16.07B
Find detailed analytics on GMAB stock on TipRanks’ Stock Analysis page.